Canadian Cancer Trials Group
Quick facts
Phase 3 pipeline
- ADT · Oncology
ADT is an androgen deprivation therapy regimen used in prostate cancer treatment to suppress testosterone production and androgen receptor signaling. - Capox · Other
- Continuous PD-1 inhibitor therapy · Oncology
Continuous PD-1 inhibitor therapy blocks the PD-1 checkpoint protein on immune cells, preventing tumor cells from suppressing anti-tumor immune responses. - Darolutamide (BAY 1841788) · Oncology
Darolutamide is a non-steroidal androgen receptor inhibitor that blocks androgen signaling in prostate cancer cells. - Intermittent PD-1 inhibitor therapy · Oncology
Intermittent PD-1 inhibitor therapy blocks the PD-1 checkpoint protein on immune cells periodically, allowing the immune system to recognize and attack cancer cells in a cyclical dosing pattern.
Phase 2 pipeline
- BA3011
- BA3021 · Oncology
BA3021 is a small molecule targeting the PI3K pathway. - Docetaxel and Reolysin · Oncology
Docetaxel is a microtubule inhibitor that disrupts cell division, while Reolysin is a viral therapy that selectively infects and kills cancer cells. - Docetaxel, Reolysin and Prednisone
- ENB003
- Folfox plus Bevacizumab · Oncology
FOLFOX plus Bevacizumab inhibits angiogenesis and disrupts tumor blood supply through VEGF inhibition, while FOLFOX induces DNA damage and apoptosis in rapidly dividing cells. - Folfox plus Bevacizumab and reolysin · Oncology
Folfox plus Bevacizumab and reolysin is a combination chemotherapy regimen that targets rapidly dividing cancer cells and inhibits angiogenesis. - LND101
- RP-3500
- RP-6306
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Canadian Cancer Trials Group
What is Canadian Cancer Trials Group's pipeline?
Canadian Cancer Trials Group has 5 drugs in Phase 3, 10 in Phase 2, 3 in Phase 1. Late-stage candidates include ADT, Capox, Continuous PD-1 inhibitor therapy, Darolutamide (BAY 1841788).
Related
- Sector hub: All tracked pharma companies